stockrow
Saturday 7 November 2026
Export VRAX’s income statement to Excel — free account
Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
0.83
0.35
−29.66%
Follow VRAX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 0 | — | 0 | 0 | 0 | 0 | (31.9%) | 0 | — | — | (67.7%) | |
| Gross margin, % | — | — | — | (7.67) | (7.59) | — | (16.28) | 32.35 | (842.86) | 62.10 | +69.8 pt | ||||||
| EBT | — | — | — | (1) | (1) | (2) | (5) | (7) | (6) | (6) | +43.7% | ||||||
| EBT margin, % | — | — | — | (543.54) | (543.54) | 0.00 | (63,462.79) | (4,308.89) | (98,474.60) | (47,841.94) | (47,298.4) pt | ||||||
| Net income | — | — | — | 0 | (1) | (2) | (5) | (7) | (6) | (5) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.11 | 12.90 | 0.00 | 0.20 | 1.95 | 0.04 | 0.03 | (18.8%) | |||||
| Earnings | — | — | — | (0.62) | (69.98) | (45.75) | (127.50) | (84.00) | (40.50) | (12.64) | +65.3% | ||||||
| Cash flow | — | — | — | (0.65) | (61.48) | (21.20) | (98.35) | (77.89) | (30.59) | (11.62) | +61.5% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | (4.20) | (14.52) | (4.05) | (0.64) | n/m | ||||||
| Free cash flow | — | — | — | (0.65) | (61.48) | (21.20) | (102.55) | (92.41) | (34.63) | (12.27) | +63.0% | ||||||
| Book value | — | — | — | (0.73) | (86.65) | (31.25) | 209.51 | 64.07 | 36.61 | 18.45 | n/m | ||||||
| Shares, m | — | — | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | (16.1%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | 0.00 | 0.00 | — | 1.22 | 0.20 | 0.23 | 0.42 | 0.3 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (1) | (4) | (6) | (5) | (5) | +35.6% | |||||
| Capex | — | — | — | — | — | — | 0 | (1) | (1) | 0 | +12.8% | ||||||
| Free cash flow | — | — | — | (1) | (1) | (1) | (4) | (7) | (5) | (5) | +36.8% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | (1) | (1) | (1) | 9 | 4 | 4 | 6 | n/m | |||||
| Net debt | — | — | — | 1 | 0 | 0 | (9) | (4) | (4) | (6) | n/m | ||||||
| Shareholders’ equity | — | — | — | (1) | (1) | (1) | 9 | 5 | 5 | 7 | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (1,643.94) | (3,870.44) | (110.69) | (88.04) | (101.78) | (68.11) | (68.1) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (262.02) | (300.05) | (432.65) | (432.7) pt | ||||||
| ROE | — | — | — | 0.00 | 23.85 | 168.48 | (141.62) | (95.90) | (114.35) | (78.51) | (78.5) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | 5 | 11 | 17 | 19 | 26 | +51.0% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · fundamentals updated 26 Oct 2026
Virax Biolabs Group Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GNPX GENPREX | $1.7M | — (loss-making) | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $1.7M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GOVX GeoVax Labs Inc. | $1.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | |
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| Median of peers | $1.6M | — | — | +147.13% | — | −49.67% | 97.44% | 0.00% |